The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. | Journal of Psychopharmacology | 30 April 2018
Acute pharmacological effects of 2C-B in humans: An observational study
Papaseit, E., Farré, M., Perez-Maña, C., Torrens, M., Ventura, M., Pujadas, M., ... & González, D. | Frontiers in Pharmacology | 13 March 2018
Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats
Elmore, J. S., Decker, A. M., Sulima, A., Rice, K. C., Partilla, J. S., Blough, B. E., & Baumann, M. H. | Neuropharmacology | 1 March 2018
Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice
Buchborn, T., Lyons, T., & Knöpfel, T. | Frontiers in Pharmacology | 6 Februari 2018
The experience elicited by hallucinogens presents the highest similarity to dreaming within a large database of psychoactive substance reports
Tagliazucchi, E., & Sanz, C. | Frontiers in Neuroscience | 4 January 2018
Novel psychotherapeutics – a cautiously optimistic focus on Hallucinogens
Sherwood, A. M., & Prisinzano, T. E. | Expert Review of Clinical Pharmacology | 17 December 2017
The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1A and 5-HT2A receptors
Riga, M. S., Lladó-Pelfort, L., Artigas, F., & Celada, P. | Neuropharmacology | 6 December 2017
A regulatory perspective on the evaluation of hallucinogen drugs for human use
Calderon, S. N., Hunt, J., & Klein, M. | Neuropharmacology | 24 November 2017
The ‘Endless Trip’: Psychopathology and Psychopharmacology in the Hallucinogen Persisting Perception Disorder/HPPD and the NPS. A systematic review
Orsolini, L., Papanti, G. D., De Berardis, D., Guirguis, A., Corkery, J. M., & Schifano, F. | Frontiers in Psychiatry | 20 November 2017
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences
Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. | Psychopharmacology | 7 November 2017
Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
Dakic, V., Nascimento, J. M., Sartore, R. C., de Moraes Maciel, R., Araujo, D. B., Ribeiro, S., ... & Rehen, S. K. | Scientific Reports | 9 October 2017
The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology
Winkelman, M. J. | Frontiers in Neuroscience | 28 September 2017
Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review
Reiche, S., Hermle, L., Gutwinski, S., Jungaberle, H., Gasser, P., & Majić, T. | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 22 September 2017
Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
Argento, E., Strathdee, S. A., Tupper, K., Braschel, M., Wood, E., & Shannon, K. | BMJ open | 21 September 2017
Psi and Psychedelics; Meditation and Mysticism: Religion, Science, and Non-Ordinary States of Consciousness
Barnard, G. W. | Religious Studies Review | 13 September 2017
MDA, MDMA and other mescaline-like substances in the US military’s search for a truth drug (1940s to 1960s)
Passie, T., & Benzenhöfer, U. | Drug testing and analysis | 29 August 2017
Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs
Hassan, Z., Bosch, O. G., Singh, D., Narayanan, S., Kasinather, B. V., Seifritz, E., ... & Müller, C. P. | Frontiers in psychiatry | 18 August 2017
Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology
Kelmendi, B., Adams, T. G., Southwick, S., Abdallah, C. G., & Krystal, J. H. | Clinical Psychology: Science and Practice | 18 July 2017
Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)
Luethi, D., Trachsel, D., Hoener, M. C., & Liechti, M. E. | Neuropharmacology | 15 July 2017
In vitro antiviral effects of Peganum harmala seed extract and its total alkaloids against Influenza virus
Moradi, M. T., Karimi, A., Rafieian-Kopaei, M., & Fotouhi, F. | Microbial Pathogenesis | 16 June 2017
Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)
Brandt, S. D., Kavanagh, P. V., Twamley, B., Westphal, F., Elliott, S. P., Wallach, J., ... & Halberstadt, A. L. | Drug Testing and Analysis | 5 June 2017
Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution
Millière, R. | Frontiers in Human Neuroscience | 23 May 2017
Genie in a blotter: A comparative study of LSD and LSD analogues’ effects and user profile
Coney, L. D., Maier, L. J., Ferris, J. A., Winstock, A. R., & Barratt, M. J. | Human Psychopharmacology: Clinical and Experimental | 18 May 2017
A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, prevents the shift to a drug-dependent state and the expression of withdrawal aversions in rodents
Vargas‐Perez, H., Grieder, T. E., Ting‐A‐Kee, R., Maal‐Bared, G., Chwalek, M., & van der Kooy, D. | European Journal of Neuroscience | 4 May 2017
A Longitudinal Study of Self-Reported Psychopathology in Beginning Ecstasy and Amphetamine Users: A Third Follow-Up Evaluation
Wagner, D., Sauder, T., Koester, P., Gouzoulis-Mayfrank, E., & Daumann, J. | Substance Use & Misuse | 4 May 2017